GT Biopharma (NASDAQ: GTBP) has announced a significant financial development through the exercise of existing warrants, securing approximately $0.7 million in gross proceeds to advance its innovative natural killer (NK) cell engager platform. The transaction involves the exercise of warrants for 302,069 shares at $4.35 per share, originally issued in May 2024.
Strategic Warrant Restructuring
The company has structured the deal to include immediate warrant exercises at a modified price of $2.27 per share, complemented by the issuance of new unregistered warrants. These new instruments allow for the purchase of up to 604,138 shares of common stock at an exercise price of $2.02 per share. The arrangement is split between two tranches: one set of warrants for 302,069 shares with a five-year term, and another for the same number of shares with an eighteen-month exercise period.
Financial Implementation and Support
H.C. Wainwright & Co. has been engaged as the exclusive placement agent for this offering, which is anticipated to conclude around February 27, 2025, subject to standard closing conditions. The company plans to direct the net proceeds toward working capital requirements and general corporate purposes, supporting its ongoing research and development initiatives.
Regulatory Compliance and Registration
The new warrants are being offered through a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. While the initial warrant shares were registered under Form S-1 (File No. 333-280326), GT Biopharma has committed to filing a registration statement with the SEC to cover the resale of shares issuable upon exercise of the new warrants.
Technology Platform and Company Focus
GT Biopharma's core technology, the TriKE® platform, represents a novel approach in immuno-oncology. This proprietary technology is designed to enhance the natural cancer-fighting capabilities of patients' NK cells. The company maintains an exclusive worldwide license agreement with the University of Minnesota for the development and commercialization of therapies using TriKE® technology.
The funding secured through this warrant exercise strengthens GT Biopharma's position as it continues to advance its clinical-stage immuno-oncology programs. This financial reinforcement comes at a crucial time as the company works to develop innovative therapeutic solutions in the competitive oncology space.
